FOXO4-DRI Research Guide: p53 Interaction, Senescence Evidence, COA, and Sourcing
Longevity Research | 2026-08-30 | 11 min read
A careful FOXO4-DRI research guide covering the D-retro-inverso peptide design, FOXO4-p53 mechanism, senescent-cell model evidence, preclinical limits, COA requirements, 10mg format, and supplier review.
What FOXO4-DRI means
FOXO4-DRI is a cell-penetrating research peptide designed to interfere with the interaction between the transcription factor FOXO4 and the tumor suppressor p53. DRI refers to a D-retro-inverso design: the sequence uses D-amino acids in reversed order to mimic selected side-chain geometry while changing proteolytic behavior.
This design detail matters for procurement. A quotation for a generic FOXO4 peptide is not automatically equivalent to FOXO4-DRI. The buyer should confirm the sequence orientation, amino-acid chirality, terminal modifications, molecular identity, and analytical specification.
The original FOXO4-p53 research
The widely cited 2017 Cell paper investigated how senescent cells resist apoptosis and identified FOXO4 as an important part of that survival mechanism. The researchers designed a FOXO4-derived D-retro-inverso peptide to disrupt FOXO4-p53 interaction. They reported selective effects in senescent-cell systems and evaluated the peptide in mouse models of chemotoxicity and aging-related loss of tissue homeostasis.
This work established an important preclinical research hypothesis. It did not establish general human efficacy, consumer safety, or a personal-use protocol. Search phrases such as FOXO4-DRI senolytic peptide and senescent cell research peptide should lead to content that names the model and preserves this evidence boundary.
Later studies do not remove the evidence limits
Subsequent studies have examined FOXO4-DRI in additional cell and animal models, including senescent Leydig cells and vascular endothelial senescence. These studies expand the mechanistic map, but much of the evidence remains cellular or preclinical. Different models also use different endpoints, exposure conditions, and material specifications.
A responsible supplier article should therefore explain what was measured without converting a model-level result into an anti-aging promise. It should also distinguish the catalog product from a clinical-grade investigational material.
COA requirements for a D-retro-inverso peptide
FOXO4-DRI identity depends on more than the letters in a sequence. Chirality and sequence direction are defining attributes. Mass spectrometry can support molecular mass, and HPLC can support chromatographic purity, but a qualification program may need sequence documentation, amino-acid configuration confirmation, peptide content, counterion data, water content, or another orthogonal method.
Ask the supplier:
- Is the material explicitly D-retro-inverso FOXO4-DRI rather than a generic FOXO4 fragment?
- Are sequence, chirality, terminal groups, and molecular formula documented?
- Do the vial label and COA share the same product code and lot number?
- Which method supports identity and which method supports purity?
- Does the quantity represent gross lyophilized mass or net peptide content?
- Are counterion, water, storage, light protection, and packaging stated?
An HPLC area percentage alone cannot establish sequence orientation or D-amino-acid configuration. The analytical package should match the identity risk of the product.
Comparing FOXO4-DRI 10mg quotations
ZePeptide lists FOXO4-DRI in a 10mg x 10-vial research format. Compare total material, vial count, COA scope, sequence documentation, shipping, and batch traceability before comparing price. A low quotation is not equivalent if it describes an unverified FOXO4 fragment or omits the D-retro-inverso identity.
For repeat laboratory work, record batch-specific chromatography, mass data, quantity basis, and storage history. Changes in salt form, moisture, or analytical release criteria can affect comparability even when the product name stays the same.
ZePeptide supplies FOXO4-DRI for lawful laboratory research only. This article is an evidence and procurement guide, not medical advice or a recommendation for human or veterinary use.
ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.